SynAct Pharma strengthens its patent portfolio for AP1189 following an Intention to Grant from the European Patent Office
SynAct Pharma AB (“SynAct”) today announced that the European Patent Office (EPO) has issued an Intention to Grant for the company’s European patent application covering AP1189 in methods of treating arthritic diseases.SynAct has received information that an Intention to Grant has been issued concerning its European patent application 20723141.6 (EP publication 3773558). The European patent, when granted, will provide protection until 2040 for the use of SynAct’s lead compound AP1189 in combination with methotrexate in methods of treating arthritic disease, including Rheumatoid Arthritis,